C57 - Effective Cytoreduction Can Be Achieved in Patients with Numerous Neuroendocrine Tumor Liver Metastases

Published in 2018 Listed under Clinical

Download

Abstract ID: 4

Aaron Scott, Patrick Breheny, Kendall Keck,  Andrew Bellizzi, Joseph Dillon,  Thomas O’Dorisio,  James Howe

C57 - Metastatic Potential of Small Pancreatic Neuroendocrine Tumors: Not as Innocent as They Seem

Published in 2019 Listed under Clinical

Download

Eduardo Vega; Onur Kutlu; Omid Salehi; Daria James; Olga Kozyreva; Jennifer Chan; Claudius Conrad

Abstract ID: 155

C57 – Assessment of Disease Aggression in Cystic Pancreatic NET: a CT and Pathology Correlation Study

Published in 2017 Listed under Clinical

Download

Yano

Abstract ID: 202

C58 - Management of Small Asymptomatic Nonfunctioning Pancreatic Neuroendocrine Tumors: Limitations to Apply Guidelines into Real Life

Published in 2019 Listed under Clinical

Download

Valentina Andreasi; Stefano Partelli; Michele Mazza; Francesca Muffatti; Stefano Crippa; Domenico Tamburrino; Massimo Falconi

Abstract ID: 159

C58 - The Pancreas as a Site of Metastasis or Second Primary in Patients with Small Bowel Neuroendocrine Tumors

Published in 2018 Listed under Clinical, Poster

Download

Abstract ID: 6

Aaron Scott, Daniel Pelletier, Jessica Maxwell, Scott Sherman, Guiying Li, Joseph Dillon, Thomas O’Dorisio, Andrew Bellizz, James Howe

  pdf Download Poster (6.05 MB)

C58 – Chronic use of Long-acting Somatostatin Analogues (SSAs) and Exocrine Pancreatic Insufficiency (EPI) in patients with Gastroenteropancreatic neuroendocrine tumors (GEP-NETs): An Under-recognized Adverse Effect

Published in 2017 Listed under Clinical, Poster

Download

C59 - Grade Switch and Survival in a Cohort of 95 Resected Pancreatic Neuroendocrine Neoplasms (PanNEN)

Published in 2018 Listed under Clinical, Poster

Download

Abstract ID: 105

Nikolaos Trikalinos, Chet Hammill,  Gregory Williams,  William Hawkins, Deyali Chatterjee

  pdf Download Poster (231 KB)

C59 - Presacral Neuroendocrine Tumors Associated with the Currarino Syndrome

Published in 2019 Listed under Clinical

Download

Aaron Scott; Jonathon Tessmann; Terry Braun; Bart Brown; Patrick Breheny; Benjamin Darbro; Andrew Bellizzi; Joseph Dillon; Thomas O'Dorisio; Alice Alderson; Bonita Bennett; John Bernat; David Metz; James Howe

Abstract ID: 167

C6 - A Pilot Study of the Cyclin Dependent Kinases 4, 6 Inhibitor Ribociclib in Patients with Foregut Neuroendocrine Tumors

Published in 2018 Listed under Clinical, Poster

Download

 Abstract ID: 38

Arvind Dasari, Daniel Halperin, Tapia Coya, Isabel Zorrilla, Funda Meric-Bernstam, James Yao

pdf Download Poster (505 KB)

C6 - Randomized Phase II Trial of Pazopanib versus Placebo in Patients (Pts) with Progressive Carcinoid Tumors (CARC) (Alliance A021202)

Published in 2019 Listed under Clinical

Download

Emily Bergsland; Michelle Mahoney; Tim Asmis; Nathan Hall; Priya Kumthekar; Michael Maitland; Donna Neidzwiecki; Andrew Nixon; Eileen O’Reilly; Lawrence Schwartz; Jeff Sloan; Jonathan Strosberg; Jeff Meyerhardt

Abstract ID: 85

C60 - Merkel Cell Carcinoma: Clinical Outcome and Prognostic Factors in 351 Patients

Published in 2018 Listed under Clinical

Download

Abstract ID: 40

Linde van Veenendaal, Alexander van Akkooi, Cees Verhoef, Dirk Jan Grünhagen, Martin Klop, Gerlof Valk, Margot Tesselaar

C60 - Primary Neuroendocrine Neoplasms of the Kidney, A Distinct Entity but Classifiable-Like the Gastroenteropancreatic Neuroendocrine Neoplasms

Published in 2019 Listed under Clinical

Download

Manik Amin; Deyali Chatterjee

Abstract ID: 168

C61 - Clinical Utility of a Molecular Cancer Classifier for Primary Site Identification in Neuroendocrine Tumors

Published in 2018 Listed under Clinical, Poster

Download

Abstract ID: 111

Brianne A. Voros, Cody Gulizo, J. Philip Boudreaux, Ramcharan Thiagarajan, Robert A. Ramirez, Eugene A. Woltering

  pdf Download Poster (986 KB)

C62 - Plasma Pancreastatin Levels Predict the Outcome of Surgical Cytoreduction in Neuroendocrine Tumors of the Small Bowel

Published in 2018 Listed under Clinical, Poster

Download

Abstract ID: 69

Eugene A. Woltering, Brianne A. Voros,  Ramcharan Thiagarajan, David T. Beyer, Robert A. Ramirez,  Gregg Mamikunian, J. Philip Boudreaux

  pdf Download Poster (854 KB)

C63 - Role of Plasma Pancreastatin in Predicting Prognosis Following R0/R1 Surgical Cytoreduction in Small Bowel Neuroendocrine Tumors

Published in 2018 Listed under Clinical, Poster

Download

Abstract ID: 65

Eugene A. Woltering, Brianne A. Voros, Ramcharan Thiagarajan, David T. Beyer, Robert A. Ramirez, Gregg Mamikunian, J. Philip Boudreaux

  pdf Download Poster (885 KB)

C64 - Clinicopathological Characteristics and Risk Factors for Recurrence of Well Differentiated Pancreatic Neuroendocrine Tumors After Radical Surgery

Published in 2018 Listed under Clinical, Poster

Download

Abstract ID: 100

Pan Zhang, Yuan-liang Li, Xu-dong Qiu, Huang-ying Tan

  pdf Download Poster (558 KB)

C7 - Outcomes after Cessation of Therapy with Alkylating Agents (AA) For Pancreatic Neuroendocrine Tumors (PanNETs)

Published in 2019 Listed under Clinical

Download

Y. Linda Wu; Diane Reidy; Agata Bielska; Virginia Kelly; Nitya Raj

Abstract ID: 92

C7 - Real-world Analysis of Long-Term Treatment Patterns and Clinical Outcomes among Patients with Advanced Neuroendocrine Tumors of Lung Origin: A Multicenter Study

Published in 2018 Listed under Clinical

Download

Abstract ID: 27

Arvind Dasari,  Emily K. Bergsland, Al B. Benson, Beilei Cai, Lynn Huynh, Todor Totev, Jesse Shea, Mei Sheng Duh,  Maureen P. Neary,  Matthew H. Kulke

C8 - Analysis of Factors Related to Gallstones in Patients with Neuroendocrine Tumors Treated with Long-Acting Somatostatin Analogues

Published in 2019 Listed under Clinical

Download

Zhirong Qi; Xudong Qiu; Yuanliang Li; Dou Dou; Jie Luo; Fei Su; Huangying Tan

Abstract ID: 97

C8 - Tumor Growth and Regression Rate Constants from the CLARINET Study as Surrogate Endpoints for Progression-Free Survival: A Novel Assessment Approach in Cancer Therapy

Published in 2018 Listed under Clinical, Poster

Download

Abstract ID: 93

Clarisse Dromain, Arturo Loaiza-Bonilla, Thomas Beveridge, Beloo Mirakhur, Julia Wilkerson, Tito Fojo

  pdf Download Poster (9.18 MB)

C9 - PD-1 Blockade in Advanced Adrenocortical Carcinoma

Published in 2019 Listed under Clinical

Download

Nitya Raj; Youyun Zheng; Virginia Kelly; Seth Katz; Joanne Chou; Richard Do; Marinela Capanu; Dmitriy Zamarin; Leonard Saltz; Charlotte Ariyan; Brian Untch; Eileen O’Reilly; Anuradha Gopalan; Michael Berger; Elly Olino; Neil Segal; Diane Reidy

Abstract ID: 118

C9 - Relationship Between Metabolic Toxicity and Efficacy of Everolimus in Patients with Neuroendocrine Tumors (NETs): A Pooled Analysis From the Randomized, Phase 3 RADIANT-3 and RADIANT-4 Trials

Published in 2018 Listed under Clinical, Poster

Download

 Abstract ID: 24

Nicola Fazio, Carlo Carnaghi, Juan W Valle, Fabian Herbst, Antonia Ridolfi, Jonathan Strosberg, Matthew Helmut Kulke, Marianne Pavel, James C Yao

pdf Download Poster (3.31 MB)

[C10] Gambardella - An ongoing phase I trial of the DLL3/CD3 IgG-like T-cell engager, BI 764532, in patients with DLL3-positive extrapulmonary neuroendocrine carcinomas

Published in 2023 Listed under Clinical

Download

[C10] Pelle - ACTH-secreting Pancreatic Neuroendocrine Neoplasms: A Case-Series

Published in 2022 Listed under Clinical

Download

[C10] Strosberg - RZ358 (Ersodetug) as a Novel Therapy for Hypoglycemia due to Tumor Hyperinsulinism: Outcomes from an Expanded Access Program for Compassionate Use

Published in 2024 Listed under Clinical

Download

[C11] McGlothlin - Transformation of Low-Intermediate Grade Neuroendocrine Tumors into High Grade Morphology

Published in 2023 Listed under Clinical

Download

[C11] Orenbach - Results from the Phase 1, Randomized, Open-Label, Cross-Over Study to Evaluate Pharmacokinetics of Three Escalating Doses of Oral Octreotide Capsules

Published in 2022 Listed under Clinical

Download

[C11] Pattnaik - Survivin and DLL-3 as predictors of survival in low-grade neuroendocrine tumor patients

Published in 2024 Listed under Clinical

Download

[C12] Capdevila - Updated Phase 1 data for the DLL3/CD3 IgG-like T-cell engager BI 764532 in DLL3-positive tumors: focus on extrapulmonary neuroendocrine carcinomas

Published in 2024 Listed under Clinical

Download

[C12] Phillips - Real world use of virtual care for treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

Published in 2023 Listed under Clinical

Download

[C12] Roy - Financial Toxicity and Supportive Care in Neuroendocrine Tumor: A Biobank Study

Published in 2022 Listed under Clinical

Download

[C13] Blanford - Serum Serotonin Compared to Plasma 5-HIAA and Chromogranin A as Biomarkers of Response to Hepatic Artery Bland Embolization

Published in 2022 Listed under Clinical

Download

[C13] Eslinger - Clinical characteristics and molecular profiling of patients with pancreatic mixed acinar-neuroendocrine carcinoma

Published in 2023 Listed under Clinical

Download

[C13] Mulla - Patterns of long-term remission or apparent cure in a cohort of patients with grade 3 neuroendocrine neoplasms (NENs)

Published in 2024 Listed under Clinical

Download

[C13] Poster - Mulla - Patterns of long-term remission or apparent cure in a cohort of patients with grade 3 neuroendocrine neoplasms (NENs)

Published in 2024 Listed under Clinical, Poster

Download

[C14] Schnell - Cabozantinib as salvage therapy for well differentiated grade 3 neuroendocrine tumors (G3 NETs)

Published in 2023 Listed under Clinical

Download

[C14] Shrestha - Approach Integrating ERCP with Radiofrequency Ablation for Long-term Management for metastatic pancreatic NET to biliary tree as klatskin tumor

Published in 2024 Listed under Clinical

Download

[C15] Chauhan - Phase II study of frontline maintenance rucaparib in combination with nivolumab in extensive stage small cell lung cancer

Published in 2023 Listed under Clinical

Download

[C15] Delpassand - Effectiveness and Safety of Re-Treatment with 177Lu- DOTATATE in Patients With Progressive NETs in the US: a Retrospective Real-World Study

Published in 2022 Listed under Clinical

Download

[C15] Poster - Shaheen - RECIST for the real world: Impact of Response Evaluation Criteria in Solid Tumors compared to standard radiology reports on p hys ician decisions and patient satisfaction

Published in 2024 Listed under Clinical, Poster

Download

[C15] Shaheen - RECIST for the real world: Impact of Response Evaluation Criteria in Solid Tumors compared to standard radiology reports on physician decisions and patient satisfaction

Published in 2024 Listed under Clinical

Download

[C16] Khuong Le - Comparison of Well-differentiated Gastroenteropancreatic Grade 3 Neuroendocrine Tumors (G3NETs): De Novo and In The Setting of Apparent Grade Progression Over Time

Published in 2023 Listed under Clinical

Download

[C16] Strosberg - Targeted Alpha Therapy with 212Pb-DOTAMTATE in subjects with advanced somatostatin receptor-expressing gastroenteropancreatic neuroendocrine tumors

Published in 2024 Listed under Clinical

Download

[C17] Ana - Argentinian Registry of Gastric Neuroendocrine Tumors: A closer look at Type 1

Published in 2023 Listed under Clinical

Download

[C17] Halperin - ACTION-1 phase Ib/3 trial of RYZ101 in gastroenteropancreatic neuroendocrine tumors progressing after 177Lu somatostatin analogue therapy: Phase 1b safety/efficacy

Published in 2024 Listed under Clinical

Download

[C18] del Rivero - DNA Damage Repair Mutational Status’s Effect on Lu-177- DOTATATE in Combination with Olaparib in Metastatic SSTR+ GI Neuroendocrine Tumor: Preliminary Results

Published in 2024 Listed under Clinical

Download

[C18] Grage - [68Ga] DOTA-TATE (NETSpot) PET/CT Imaging of Pulmonary Neuroendocrine Tumors

Published in 2023 Listed under Clinical

Download

[C18] Soulen - Radiosensitization for TARE: Does Duration of Chemotherapy Affect PFS?

Published in 2022 Listed under Clinical

Download

[C19] Moselam - Safety of Lutetium-177 DOTATATE Treatment in Patients with Advanced Neuroendocrine Tumors and Extensive/ Innumerable Bone Metastases

Published in 2024 Listed under Clinical

Download

[C19] Poster - Mosalem - Safety of Lutetium-177 DOTATATE Treatment in Patients with Advanced Neuroendocrine Tumors and Extensive/Innumerable Bone Metastases

Published in 2024 Listed under Clinical, Poster

Download

[C19] Yadav - The Impact of Post-Treatment Imaging in Peptide Receptor Radionuclide Therapy

Published in 2023 Listed under Clinical

Download

[C1] Mohamed - NP-101 in Combination with Nivolumab and Ipilimumab in Metastatic Extra-pulmonary Neuroendocrine Carcinomas (EP-NECs): A Pilot Study

Published in 2024 Listed under Clinical

Download

[C1] Poster - Mohamed - NP-101 in Combination with Nivolumab and Ipilimumab in Metastatic Extra-pulmonary Neuroendocrine Carcinomas (EP-NECs): A PIlot Study

Published in 2024 Listed under Clinical, Poster

Download

[C1] Singh - Progression-Free Survival in Patients with Bronchopulmonary Neuroendocrine Tumors Treated with Lanreotide or Placebo: Adjustment for Crossover Effects in Placebo Arm

Published in 2022 Listed under Clinical

Download

[C20] Jimenez - Quality of Life Assessments for Advanced Pheochromocytoma and Paraganglioma Patients that Received High-Specific-Activity I-131 MIBG: Results from a Pivotal Phase 2 Clinical Trial

Published in 2022 Listed under Clinical

Download

[C20] Sriwastwa - Imaging, Clinical, and Safety Outcomes in Metastatic Neuroendocrine Tumor Patients Treated with Peptide Receptor Radionuclide Therapy in the Midwestern USA

Published in 2024 Listed under Clinical

Download

[C20] Yuan - Yttrium 90 transarterial radioembolization of neuroendocrine liver metastasis

Published in 2023 Listed under Clinical

Download

[C21] Coston - Characterizing Bone Metastases in Patients with Well-Differentiated Neuroendocrine Neoplasms Utilizing Ga68-DOTATATE PET

Published in 2022 Listed under Clinical

Download

[C21] del Rivero - Effect of Absorbed Dose on Toxicity and Tumor Response of Lu-177-DOTATATE With Olaparib in Gastroenteropancreatic Neuroendocrine Patients: Preliminary Results

Published in 2024 Listed under Clinical

Download

[C21] Lin - Ratio of total uptake volume on DOTATATE vs FDG PET as a predictive marker of treatment efficacy of Lu-177- DOTATATE in metastatic pheochromocytoma

Published in 2023 Listed under Clinical

Download

[C22] Lin - Phase 2 Trial of Lu-177-DOTATATE in Metastatic or Inoperable Pheochromocytoma/Paraganglioma: Interim Analysis Results

Published in 2023 Listed under Clinical

Download

[C22] Porfido - Multicenter clinical registry of patients with a neuroendocrine tumor (NET) diagnosis receiving 177Lu-DOTATATE

Published in 2024 Listed under Clinical

Download

[C22] Poster - Porfido - Multicenter clinical registry of patients with a neuroendocrine tumor (NET) diagnosis receiving 177Lu - DOTATATE

Published in 2024 Listed under Clinical, Poster

Download

[C22] Prela - The Role of 68Ga-DOTATATE PET/CT in the Management of Gastrointestinal and Pancreatic Neuroendocrine Tumors

Published in 2022 Listed under Clinical

Download

[C23] Al-Toubah - Somatostatin Receptor Expression in Lung Neuroendocrine Tumors: An Analysis of Dotatate PET Scans

Published in 2022 Listed under Clinical

Download

[C23] Lin - Phase 1/2 study of Lu-177-DOTATATE in combination with olaparib in metastatic or inoperable GI neuroendocrine tumors - first results

Published in 2023 Listed under Clinical

Download

[C23] Porfido - Neuroendocrine tumor (NET) progression of disease during or within one year after completion of therapy with 177Lu-DOTATATE

Published in 2024 Listed under Clinical

Download

[C23] Poster - Porfido - Neuroendocrine tumor (NET) progression of disease during or within one year after completion of therapy with 177Lu - DOTATATE

Published in 2024 Listed under Clinical, Poster

Download

[C24] Barnett - Evaluating Time to Treatment Start for Patients Receiving Peptide Receptor Radioligand Therapy

Published in 2024 Listed under Clinical

Download

[C24] Mittra - MIBG and DOTATATE Therapy for Pheochromocytoma and Paraganglioma: A Single Institution Experience

Published in 2022 Listed under Clinical

Download

[C24] Nunez - 68Ga-DOTATATE/18F-FDG dual PET: Utility of the NETPET score in management of G2-3 WD NENs

Published in 2023 Listed under Clinical

Download

[C25] Fidelman - A Pilot Study of Pembrolizumab and Peptide Receptor Radionuclide Therapy for Patients with Metastatic Well- Differentiated Neuroendocrine Tumors

Published in 2023 Listed under Clinical

Download

[C25] Heying - Evaluation of 68Ga-DOTATATE PET After Two Cycles of Peptide Receptor Radionuclide Therapy (PRRT) in Neuroendocrine Tumors (NET)

Published in 2022 Listed under Clinical

Download

[C25] O'Leary - Does Liver Tumor Morphology Predict Outcomes after LDT, PRRT or CapTem?

Published in 2024 Listed under Clinical

Download

[C25] Poster - O'Leary - Associations between patterns of neuroendocrine liver metastatic burden and outcomes after embolization, CapTem and PRRT

Published in 2024 Listed under Clinical, Poster

Download

[C26] Fidelman - A Pilot Study of Pembrolizumab and Embolization or 90Y Radioembolization for Patients with Metastatic Well- Differentiated Neuroendocrine Tumors

Published in 2023 Listed under Clinical

Download

[C26] Mallak - Pre-therapy Functional Imaging with MIBG and DOTATATE to Guide Radiopharmaceutical Therapy for Pheochromocytoma and Paraganglioma: A Single Institution Experience

Published in 2022 Listed under Clinical

Download

[C26] Meredith - Incidence and Characterization of Carcinoid Crises post Embolization of Neuroendocrine Tumor Liver Metastases

Published in 2024 Listed under Clinical

Download

[C27] Chauhan - ETCTN 10388: A first in human Phase I Trial of Triapine and Lutetium Lu 177 DOTATATE in Well-Differentiated Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Published in 2023 Listed under Clinical

Download

[C27] Fidelman - A Pilot Study of Pembrolizumab and Peptide Receptor Radionuclide Therapy for Patients with Well-Differentiated Neuroendocrine Tumors and Symptomatic and/or Progressive Metastases

Published in 2024 Listed under Clinical

Download

[C27] Jha - Performance of 68Ga-DOTATATE PET/CT, 18F-FDG PET/CT, CT, and MRI Spine in the Detection of Spinal Bone Metastases in Metastatic Pheochromocytoma/Paraganglioma

Published in 2022 Listed under Clinical

Download

[C27] Poster - Fidelman - A Pilot Study of Pembrolizumab and Peptide Receptor Radionuclide Therapy for Patients with Metastatic Grade 2/3 Well - Differentiated Neuroendocrine Tumors

Published in 2024 Listed under Clinical, Poster

Download

[C28] Chauhan - ETCTN 10450: A phase I trial of peposertib and lutetium 177 DOTATATE in well-differentiated somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Published in 2023 Listed under Clinical

Download

[C28] Jha - Diagnostic Performance of PET or PET/CT Utilizing 18F-DOPA, 68Ga-DOTATATE, 18F-FDG, 18F-FDA, and CT and MRI in the Detection of MEN2A-relatedpheochromocytoma

Published in 2022 Listed under Clinical

Download

[C28] Poster - Zhou - Liver - directed therapy for metastatic neuroendocrine carcinoma and grade 3 well - differentiated neuroendocrine tumors

Published in 2024 Listed under Clinical, Poster

Download

[C28] Zhou - Liver-directed therapy for metastatic neuroendocrine carcinoma and grade 3 well-differentiated neuroendocrine tumors

Published in 2024 Listed under Clinical

Download

[C29] D'Souza - Initial Outcomes of Integrating Yttrium-90 Radioembolization with Capecitabine-Temozolomide for Grade 3 Liver-Dominant Metastatic Neuroendocrine Tumors

Published in 2024 Listed under Clinical

Download

[C29] Jha - Diagnostic Performance of PET or PET/CT Utilizing 18F-DOPA, 68Ga-DOTATATE, 18F-FDG, 18F-FDA, and CT and MRI the Detection of VHL-related Pheochromocytoma

Published in 2022 Listed under Clinical

Download

[C29] Pelle - Small bowel ischemia in patients with midgut neuroendocrine tumors after treatment with 177Lutetium-Dotatate

Published in 2023 Listed under Clinical

Download

[C29] Poster - D'Souza - Integrating Yttrium - 90 Radioembolization with Capecitabine - Temozolomide for Grade 3 Liver - Dominant Metastatic Neuroendocrine Tumors: Initial Outcomes

Published in 2024 Listed under Clinical, Poster

Download

[C2] Hunter - Pembrolizumab for the Treatment of Recurrent High Grade Neuroendocrine Neoplasms

Published in 2022 Listed under Clinical

Download

[C2] Sun - Preliminary clinical activity of surufatinib combined with octreotide LAR in patients with G1/2 gastroenteropancreatic neuroendocrine tumor (GEP-NET)

Published in 2024 Listed under Clinical

Download

[C2] Urrego - Neuroendocrine tumor metastatic to breast: case report and review of the literature

Published in 2023 Listed under Clinical

Download

[C30] Lareef - Novel Alternate (Alt) Response Criteria for early outcome prediction in Pancreatic (P) Neuroendocrine Tumors (NETs): Utilizing banked imaging and radiomics

Published in 2023 Listed under Clinical

Download

[C30] Maratta - Somatostatin receptor expression of gastroenteropancreatic neuroendocrine tumors: A comprehensive analysis of expression in the era of somatostatin receptor PET imaging

Published in 2024 Listed under Clinical

Download

[C30] Meloche-Dumas - Liver-Directed Therapy of Neuroendocrine Liver Metastases

Published in 2022 Listed under Clinical

Download

[C31] Al-Ward - High-Specific-Activity Iodine-131-Meta-Iodo- Benzylguanidine for the Treatment of Advanced Pheochromocytoma and Paraganglioma: A Real-World Study

Published in 2023 Listed under Clinical

Download

[C31] Patel - Goblet Cell Adenocarcinoma (GCA) of the Appendix: Interrogating Proteomics to Identify Potential Actionable Targets

Published in 2022 Listed under Clinical

Download

[C31] Singh - First-Line Efficacy of [177Lu]Lu-DOTA-TATE in Gastroenteropancreatic Neuroendocrine Tumors by Tumor Grade and Primary Origin: Phase 3 NETTER-2 Subgroup Analysis

Published in 2024 Listed under Clinical

Download

[C32] Bilgin - Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE in Patients with Malignant Pheochromocytoma (PCC) and Paraganglioma (PGL): A Single Institution Retrospective Study

Published in 2024 Listed under Clinical

Download